Traditionally, PH1 has been treated through conservative strategies, such as hyperhydration, crystallization inhibitors (e.g., potassium citrate) and pyridoxine (an AGT co-factor) to slow disease progression, until Lumasiran was approved by the EMA and the U.S. Food and Drug Administration (FDA) in 2020 as an orphan drug for PH1 [16]. This evidence concerns the gene AGT and primary hyperoxaluria type 1.